Beyond urodynamics: non-invasive approaches to diagnosing detrusor underactivity in men with lower urinary tract symptoms - a systematic review

超越尿动力学:诊断男性下尿路症状逼尿肌功能减退的非侵入性方法——系统评价

阅读:1

Abstract

BACKGROUND: To evaluate and synthesize existing evidence on non-invasive methods for diagnosing detrusor underactivity (DU) in men presenting with lower urinary tract symptoms (LUTS), focusing on their feasibility and diagnostic accuracy. METHODS: A systematic search of PubMed, Scopus, and Web of Science databases was conducted for original articles reporting on non-invasive diagnostic tests for DU in men with LUTS. Data extraction focuses on study characteristics, diagnostic methods, and accuracy. The risk of bias was assessed using the QUADAS-2 tool. RESULTS: Eighteen studies involving 7390 patients, of whom 3194 were diagnosed with DU, were included in our analysis. The evaluated diagnostic methods included ultrasound parameters, biomarkers, uroflowmetry results, symptom questionnaires, and clinical characteristics. Developed models, including those based on artificial intelligence (AI), and nomograms were also assessed. The symptom questionnaire DUA-SQ showed the highest sensitivity of 95.8%, while ultrasound measurements, such as detrusor wall thickness showed 100% specificity but limited sensitivity (42%). Models incorporating clinical variables achieved sensitivity rates of over 75%. Uroflowmetry parameters, particularly presence of "sawtooth" and "interrupted" waveforms, demonstrated sensitivity of 80% and specificity of 87%. Biomarkers, including serum adiponectin and urine NO/ATP ratio, achieved sensitivity of 79% and 88.5%, respectively. AI models showed potential, with sensitivities ranging from 65.9% to 79.7%. Due to the poor quality of the studies and data heterogeneity, meta-analysis was not performed. CONCLUSIONS: Non-invasive diagnostic methods for DU, particularly DUA-SQ, ultrasound measurements, and AI models, demonstrate potential, though their accuracies vary. Further research is needed to standardize these methods and enhance their diagnostic reliability. TRIAL REGISTRATION: The study protocol was registered with PROSPERO (CRD42024556425). CLINICAL TRIAL NUMBER: not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。